Weekly everolimus and resistance training to boost bone health in postmenopausal women

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Postmenopausal women aged 60–75 with low bone mass (DXA T-score between -1.0 and -2.5) are randomized equally into four groups: weekly everolimus, weekly placebo, everolimus plus thrice-weekly one-hour resistance training, or placebo plus the same training. Participants attend 5–7 visits for blood tests, DXA and MRI scans (HR-pQCT at Odense), muscle and bone biopsies, quality-of-life questionnaires, and muscle function testing. The trial compares changes in bone formation markers, bone density/structure, and muscle function between the groups over the study period. Major exclusions include established osteoporosis, recent low-energy fractures, impaired wound healing, untreated vitamin D deficiency, and conditions limiting weight-bearing exercise.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Women aged 60-75 years old, any ethnicity.
* Participants with T- score between \< 1.0 and \> -2.5 measured by DXA scan within 6 months of the first day of the study.
* Adequate cognitive function to be able to give informed consent.

Exclusion Criteria:

* Osteoporosis and fracture history

  * Participants with osteoporosis (defined by DXA scan \< 6 months old: low bone mass, T-score \< -2.5 or hip fracture or clinical compression fracture of the spine).
  * History of low energy fractures within last 6 months. Health conditions limiting exercise
  * Health conditions that could limit walking and weightbearing exercise (for instance recent surgery, mobility limitation)
  * Participants with impaired wound healing or history of a chronic open wound Bone metabolism disorders
  * Primary hyperparathyroidism.
  * Known vitamin D deficiency (\<25 nM) (re-test after substitution acceptable).
  * Known disorders affecting bone metabolism, e.g., uncontrolled thyrotoxicosis, severe renal impairment (eGFR \< 30) or impaired liver function (baseline phosphatase higher than twice upper limit (105 U/L)), active rheumatic diseases, celiac disease, severe chronic obstructive lung disease (COPD), hypopituitarism, or Cushing's disease.
  * Previous use of bone antiresorptive or bone anabolic drugs within the last 5 years.

Medication use and health conditions

* Use of anabolic steroids in the previous year.
* Use of antiresorptive therapy in the previous year.
* Known medication/supplements affecting bone in the previous year.
* Diabetes type 1 and 2.
* Heart failure similar to NYHA Class IV.
* Treatment with drugs known to affect cytochrome P450 3A due to its role in everolimus metabolism, excluding strong CYP3A4 inhibitors or inducers, while allowing weak and intermediate inhibitors or inducers. Patients on the following drugs will be excluded from the trial: Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Telithromycin, Clarithromycin, Nedazodone, Ritonavir, Atazanavir, Saquinavir, Darunavir, Indinavir, Nelfinavir, Rifampicin, Dexamethasone, Carbamazepine, phenobarbital, Phenytoin, Efavirenz and Nivirapine.
* History of coagulopathy or medical condition requiring long-term anticoagulation.

Blood disorders and other health concerns

* Anemia - Hg \< 5,59 mmol/L, Leukopenia - white blood cells (WBC) \< 3,5 x 10⁹/L, Neutropenia absolute neutrophil count \< 2,0 x 10⁹/L, or Platelet count - platelet count \< 125 x 10⁹/L.
* Insufficiently treated dyslipidemia with LDL-c \> 4,9 mmol/L and family history of dyslipidemia, Total cholesterol \> 9,1 mmol/L, or triglycerides \> 9,9 mmol/L.

Immunosuppressive and current cancer Treatment

* Scheduled for immunosuppressant therapy for transplant or scheduled to undergo chemotherapy or any other treatment for malignancy
* Any form of clinically relevant primary or secondary immune dysfunction or deficiency Cardiovascular and heart conditions
* Unstable ischemic heart disease.

Allergies

* Known allergy to rapamycin or rapalogs. Language limitations
* The study will exclude participants with inability to speak and understand Danish and with inability to cooperate.

Where it's running

• Institute of Sports Medicine, Bispebjerg Hospital
  Bispebjerg, Region Sjælland, Denmark Recruiting
• Department of Endocrinology, Odense University Hospital
  Odense, Region Syddanmark, Denmark Recruiting

Study contacts

• Principal investigator: Moustapha Kassem, MD — Odense University Hospital
• Study coordinator: Sofie Elkjær, MD
• Email: anna.sofie.elkjaer3@rsyd.dk
• Phone: +4521428178

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Functional Muscle-Bone Incongruity Index: A look at muscle strength and bone health in adults

  This observational study tests a composite FKUI score using handgrip strength and hip/spine bone density to see if it better reflects musculoskeletal health than each measure alone in adults undergoing routine DXA.

  Recruiting Kanuni Sultan Suleyman Training and Research Hospital · Küçükçekmece, Istanbul · NCT07677033

• Veverimer to reduce acid load and slow bone loss in adults with osteopenia

  This trial will test whether taking veverimer, compared with placebo, lowers urinary acid levels and reduces bone breakdown in adults aged 50 and older with osteopenia.

  Recruiting Phase 1 Tufts Medical Center · Boston, Massachusetts · NCT07473713

• Using REMS ultrasound to check bone density in children and teens with conditions that lower bone strength

  This project will test whether REMS, a radiation-free ultrasound method, can measure bone mineral density in children and adolescents aged 5–18 who have conditions that weaken their bones.

  Recruiting Meyer Children's Hospital IRCCS · Florence, Tuscany · NCT07412782

• Validating lab assays, IV catheter techniques, and devices for endocrine, cardiometabolic, and musculoskeletal conditions

  This project will test whether laboratory assays, IV catheter methods, and equipment give consistent, reliable results in adults with or without obesity-related, metabolic, or musculoskeletal conditions.

  Recruiting University of Missouri-Columbia · Columbia, Missouri · NCT07083557

• High-Intensity Interval Training for Bone Health in Older Women

  This study is testing if a 24-week high-intensity workout program can help older women with low bone density feel better and improve their bone health.

  Recruiting Hong Kong Baptist University · China, Hong Kong · NCT06888544

• Vitamin K2 supplementation for patients with low bone density and a specific gene variant

  This study is testing if taking vitamin K2 can help improve bone density in adults aged 40-75 with low bone density who have a specific gene variant.

  Recruiting S.lab (Soloways) · Novosibirsk · NCT06867952

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.